Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 20, Issue 7, 2014, Pages 1208-1216

  Arai, Yoshinori ^a   Arihiro, Seiji ^a   Matsuura, Tomokazu ^a   Kato, Tomohiro ^a   Matsuoka, Mika ^a   Saruta, Masayuki ^a   Mitsunaga, Makoto ^a   Matsuura, Masaaki ^b   Fujiwara, Mutsunori ^c   Okayasu, Isao ^d   Ito, Satoru ^e,f   Tajiri, Hisao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CANCER INSTITUTE   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^d KITASATO UNIVERSITY   (Japan)

^e FUJIREBIO INC   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Activity indicator; Histologic remission; Inflammatory bowel disease; Minimally invasive

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROSTAGLANDIN E; PROSTAGLANDIN E RECEPTOR;

ADULT; ARTICLE; COLONOSCOPY; COMPARATIVE STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; URINALYSIS; COHORT ANALYSIS; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; COLITIS, ULCERATIVE; COLONOSCOPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, PROSTAGLANDIN E; RISK ASSESSMENT; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84905506667     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000062     Document Type: Article

References (39)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713-1725.
3. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet. 2002;359:331-340.
4. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology. 2005;128:1805-1811.
5. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011;33:672-678.
6. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201.
7. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338-346.
8. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
9. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis. 1966;11:847-857.
10. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174-178.
11. Karoui S, Laz S, Serghini M, et al. Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. Dig Dis Sci. 2011;56:1801-1805.
12. Turner D, Mack DR, Hyams J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis. 2011;5:423-429.
13. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20.
14. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817-1826.
15. Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108:83-89.
16. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332-341.
17. Nataraj C, Thomas DW, Tilley SL, et al. Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse. J Clin Invest. 2001;108:1229-1235.
18. Chinen T, Komai K, Muto G, et al. Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat Commun. 2011;2:190.
19. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983;3:295-315.
20. Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75:638-640.
21. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984;86:453-460.
22. Lauritsen K, Laursen LS, Bukhave K, et al. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology. 1986;91:837-844.
23. Wardle TD, Turnberg LA. Potential role for interleukin-1 in the pathophysiology of ulcerative colitis. Clin Sci (Lond). 1994;86:619-626.
24. Raab Y, Sundberg C, Hallgren R, et al. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am J Gastroenterol. 1995;90:614-620.
25. Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. Mucosal and plasma prostaglandin E2 in ulcerative colitis. Hepatogastroenterology. 1999;46:2338-2342.
26. Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8:289-293.
27. Pozzi A, Yan X, Macias-Perez I, et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem. 2004;279:29797-29804.
28. Iglesias D, Nejda N, Azcoita MM, et al. Effect of COX2-765G. C and c.3618A. G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control. 2009;20:1421-1429.
29. Xiang L, Wang S, Jin X, et al. Expression of BMP2, TLR3, TLR4 and COX2 in colorectal polyps, adenoma and adenocarcinoma. Mol Med Rep. 2012;6:973-976.
30. Hamberg M. Inhibition of prostaglandin synthesis in man. Biochem Biophys Res Commun. 1972;49:720-726.
31. Inagawa T, Imaki K, Masuda H, et al. Simplified immunoassays of prostaglandin E main metabolite in human urine. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:191-196.
32. Fujiwara M, Okayasu I, Oritsu M, et al. Significant increase in prostaglandin E-main urinary metabolite by laxative administration: comparison with ulcerative colitis. Digestion. 2000;61:201-206.
33. Okayasu I, Ohnisi H, Sarandi I, et al. Significant increase of prostaglandin E-major urinary metabolite in male smokers: a screening study of age and gender differences using a simple radioimmunoassay. J Clin Lab Anal. 2013;28:32-41.
34. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
35. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
36. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393-407.
37. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429-437.
38. Connell WR, Talbot IC, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 1994;35:1419-14123.
39. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.